Eli Lilly’s head-to-head CHALLENGE-MIG trial missed its primary endpoint Friday, failing to establish the statistical superiority of the company’s Emgality (galcanezumab-gnlm) over Pfizer’s Nurtec orally disintegrating tablets (rimegepant).
Tag Archive for: Nurtec ODT
AbbVie wins FDA approval for new migraine indication Published: Apr 19, 2023 By Tristan Manalac BioSpace The FDA has approved an expanded indication for AbbVie’s Qulipta (atogepant) to treat patients […]